Cargando…
Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from β-blockers and prostaglandin analogs
INTRODUCTION: Travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops are available in Japan. We prospectively investigated the intraocular pressure (IOP)-decreasing effect of travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops and the adherence of patients to the administr...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280104/ https://www.ncbi.nlm.nih.gov/pubmed/22347794 http://dx.doi.org/10.2147/OPTH.S29062 |
_version_ | 1782223775755927552 |
---|---|
author | Inoue, Kenji Setogawa, Akira Higa, Risako Moriyama, Ryo Wakakura, Masato Tomita, Goji |
author_facet | Inoue, Kenji Setogawa, Akira Higa, Risako Moriyama, Ryo Wakakura, Masato Tomita, Goji |
author_sort | Inoue, Kenji |
collection | PubMed |
description | INTRODUCTION: Travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops are available in Japan. We prospectively investigated the intraocular pressure (IOP)-decreasing effect of travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops and the adherence of patients to the administration protocol. MATERIALS AND METHODS: We studied 43 eyes from 43 patients diagnosed with primary open- angle glaucoma, who were using prostaglandin analogs and β-blockers. The prostaglandin analogs and β-blockers were discontinued, and the treatment regimen was changed to travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops without any washout period. IOP before and at 1 month, 3 months, and 6 months after the treatment change was evaluated and compared. A questionnaire about protocol adherence was administered 1 month after the treatment change. RESULTS: IOP was 15.7 ± 2.9 mmHg before the change, 15.5 ± 2.7 mmHg at 1 month after the change, 15.3 ± 3.6 mmHg at 3 months after the change, and 15.8 ± 3.2 mmHg at 6 months after the change, and none of the differences were significant (P = 0.191). The responses to the questionnaire showed that cases where eye drop administration was forgotten decreased after the treatment change. Moreover, because of changes in eye drops, 19.0% of patients had irritation. More than half (54.8%) of the patients preferred travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops. Seven patients (16.3%) discontinued eye drop use because of adverse reactions within 6 months after the change. CONCLUSION: When the treatment regimen was changed from prostaglandin analogs and β-blockers to travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops, administration protocol adherence increased and IOP was preserved; however, adverse reactions appeared in about 16% of the cases. |
format | Online Article Text |
id | pubmed-3280104 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-32801042012-02-17 Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from β-blockers and prostaglandin analogs Inoue, Kenji Setogawa, Akira Higa, Risako Moriyama, Ryo Wakakura, Masato Tomita, Goji Clin Ophthalmol Original Research INTRODUCTION: Travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops are available in Japan. We prospectively investigated the intraocular pressure (IOP)-decreasing effect of travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops and the adherence of patients to the administration protocol. MATERIALS AND METHODS: We studied 43 eyes from 43 patients diagnosed with primary open- angle glaucoma, who were using prostaglandin analogs and β-blockers. The prostaglandin analogs and β-blockers were discontinued, and the treatment regimen was changed to travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops without any washout period. IOP before and at 1 month, 3 months, and 6 months after the treatment change was evaluated and compared. A questionnaire about protocol adherence was administered 1 month after the treatment change. RESULTS: IOP was 15.7 ± 2.9 mmHg before the change, 15.5 ± 2.7 mmHg at 1 month after the change, 15.3 ± 3.6 mmHg at 3 months after the change, and 15.8 ± 3.2 mmHg at 6 months after the change, and none of the differences were significant (P = 0.191). The responses to the questionnaire showed that cases where eye drop administration was forgotten decreased after the treatment change. Moreover, because of changes in eye drops, 19.0% of patients had irritation. More than half (54.8%) of the patients preferred travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops. Seven patients (16.3%) discontinued eye drop use because of adverse reactions within 6 months after the change. CONCLUSION: When the treatment regimen was changed from prostaglandin analogs and β-blockers to travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops, administration protocol adherence increased and IOP was preserved; however, adverse reactions appeared in about 16% of the cases. Dove Medical Press 2012 2012-02-10 /pmc/articles/PMC3280104/ /pubmed/22347794 http://dx.doi.org/10.2147/OPTH.S29062 Text en © 2012 Inoue et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Inoue, Kenji Setogawa, Akira Higa, Risako Moriyama, Ryo Wakakura, Masato Tomita, Goji Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from β-blockers and prostaglandin analogs |
title | Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from β-blockers and prostaglandin analogs |
title_full | Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from β-blockers and prostaglandin analogs |
title_fullStr | Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from β-blockers and prostaglandin analogs |
title_full_unstemmed | Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from β-blockers and prostaglandin analogs |
title_short | Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from β-blockers and prostaglandin analogs |
title_sort | ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from β-blockers and prostaglandin analogs |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280104/ https://www.ncbi.nlm.nih.gov/pubmed/22347794 http://dx.doi.org/10.2147/OPTH.S29062 |
work_keys_str_mv | AT inouekenji ocularhypotensiveeffectandsafetyoftravoprost0004timololmaleate05fixedcombinationafterchangeoftreatmentregimenfrombblockersandprostaglandinanalogs AT setogawaakira ocularhypotensiveeffectandsafetyoftravoprost0004timololmaleate05fixedcombinationafterchangeoftreatmentregimenfrombblockersandprostaglandinanalogs AT higarisako ocularhypotensiveeffectandsafetyoftravoprost0004timololmaleate05fixedcombinationafterchangeoftreatmentregimenfrombblockersandprostaglandinanalogs AT moriyamaryo ocularhypotensiveeffectandsafetyoftravoprost0004timololmaleate05fixedcombinationafterchangeoftreatmentregimenfrombblockersandprostaglandinanalogs AT wakakuramasato ocularhypotensiveeffectandsafetyoftravoprost0004timololmaleate05fixedcombinationafterchangeoftreatmentregimenfrombblockersandprostaglandinanalogs AT tomitagoji ocularhypotensiveeffectandsafetyoftravoprost0004timololmaleate05fixedcombinationafterchangeoftreatmentregimenfrombblockersandprostaglandinanalogs |